Abstract
Purpose :
FAi is a novel therapeutic agent, and little is known about its safety profile in the real-world setting. A retrospective chart review was performed to assess the safety of long-acting FAi in the management of chronic noninfectious uveitis.
Methods :
A retrospective review of 103 eyes that received FAi was completed. Outcome variables included immediate and long-term complications such as intraocular pressure (IOP) events, visual acuity (VA) decrease, and cataract surgery events.
Results :
Results are reported as the proportion of eyes with available data at each follow up visit. There were no recorded immediate complications of the injection procedure. Anterior chamber implant migration occurred twice among all 103 eyes during the study period. Median IOP at baseline was 16 (IQR 14-19). 2% of study eyes experienced a 10 mmHg or greater increase in IOP 1 month from baseline (n=2/84), 7% at 3 months (n=5/74), and 4% at 6 months (n=3/61). IOP lowering therapy was necessary for 19% of eyes by 6 months (13/61) with two eyes requiring surgical intervention. A 2-line visual acuity decrease was reported in 6% of eyes at 1 month (5/84), 9% at 3 months (7/74) and 9% of eyes at 6 months (6/61). 4 of the 14 phakic eyes at baseline required cataract surgery by 6 months.
Conclusions :
In this series, FAi for chronic uveitis had lower rates of steroid-induced increase in IOP as compared to conventional intravitreal steroids and incidence of cataract surgery consistent with those published in the literature.
This is a 2021 ARVO Annual Meeting abstract.